Medtronic Reports the First Patient Implant in (TITAN 2) Study of Implantable Tibial Neuromodulation Device for Overactive Bladder
Shots:
- The first patient has been implanted in the (TITAN 2) study to evaluate the safety & efficacy of implantable TNM devices in 130 patients with OAB at ~30 sites in the US for 6mos. & patients will be followed for 24mos. The device helps to expand the patient's access to advanced therapy
- An implantable TNM device can reduce the burden on patients through ongoing treatments without the need for additional clinic visits. The procedure is less invasive than sacral neuromodulation
- The company plans for the regulatory submission to the US FDA for approval, following the completion of (TITAN 2) study. The company provides PTNM therapy through its NURO system & required patients visit in a clinic setting to receive therapy & return for repeat treatments
Ref: Medtronic | Image: Medtronic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
